Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12685167 | 0.90 | NR1H2 (0.43) | NR1H2NR1H3GABRA1GABRG2GABRB3 | |
| SCHEMBL29955533 | 0.84 | NR1H2 (0.48) | NR1H2NR1H3GABRA1GABRG2GABRB3 | |
| SCHEMBL12804182 | 0.84 | NR1H2 (0.48) | NR1H2NR1H3GABRA1GABRG2GABRB3 | |
| SCHEMBL757548 | 0.84 | NR1H2 (0.48) | NR1H2NR1H3GABRA1GABRG2GABRB3 | |
| SCHEMBL12803799 | 0.83 | NR1H2 (0.52) | NR1H2NR1H3GABRA1GABRG2GABRB3 | |
| SCHEMBL10173695 | 0.82 | NR1H2 (0.49) | NR1H2NR1H3GABRG2GABRB3GABRA5 | |
| SCHEMBL3001991 | 0.82 | NR1H2 (0.65) | NR1H2NR1H3 | |
| SCHEMBL18966700 | 0.81 | ESR2 (0.43) | NR1H2NR1H3GABRG2GABRB3GABRA5 | |
| SCHEMBL3012171 | 0.80 | NR1H2 (0.56) | NR1H2NR1H3CNR1 | |
| SCHEMBL4389624 | 0.80 | AKR1C3 (0.49) | NR1H2NR1H3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071533-B | Halogenated allylamine indole and azaindole derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-10-08 | — | — | US | disclosed |
| US-10717733-B2 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | PHARMAXIS LTD. (AU) | 2020-07-21 | — | — | US | disclosed |
| US-20190040007-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2019-02-07 | — | — | US | disclosed |
| WO-2017136870-A9 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2018-02-15 | — | — | WO | disclosed |
| WO-2017136870-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717733-B2 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | IDO1, IDO2, INMT | NR1H2 2636/4885NR1H3 2544/4885GABRA1 3934/4885 |
| US-20190040007-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | NR1H2 2636/4885NR1H3 2544/4885GABRA1 3934/4885 |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | NR1H2 2636/4885NR1H3 2544/4885GABRA1 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.